VSIR

Across TCGA pan-cancer cohorts, VSIR mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VSIR data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher VSIR mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated VSIR expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where VSIR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.352	0.891	.003	25	view →
HNSC	OS	Quartile	III,IV	0.964	0.166	.024	12	view →
LUAD	DFS	Median	II,III,IV	0.747	0.321	.006	9	view →
UCEC	DFS	Quartile	All	0.710	0.962	.013	8	view →
LSCC	DFS	Tertile	All	0.852	0.333	.012	3	view →
CCRCC	OS	Median	All	0.840	0.943	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VSIR–PDAC (DFS)

Open the PDAC breakdown →